Nerve regeneration tech targets Alzheimer’s and Nasdaq
Longevity Technology,
NervGen readies for NASDAQ listing and clinical trials of lead compound for nerve regeneration in 2021. With a unique nerve…
NervGen readies for NASDAQ listing and clinical trials of lead compound for nerve regeneration in 2021. With a unique nerve…
NervGen readies for NASDAQ listing and clinical trials of lead compound for nerve regeneration in 2021. With a unique nerve…
As we turn the page on 2014, here’s a list of some of the year’s highlights in neuroscience – along with a heavy dose of…
MedicalResearch.com Interview with: Bradley T. Lang, PhD Researcher, Jerry Silver Lab Department of Neurosciences Case Western…